Longitudinal studies examining associations of the inflammatory markers fibrinogen and C-reactive protein (CRP) with lung function decline are sparse. The authors examined whether elevated fibrinogen and CRP levels were associated with greater longitudinal lung function decline in the elderly. The Cardiovascular Health Study measured fibrinogen and CRP in 5,790 Whites and African Americans from four US communities aged 65 years or older in 1989 -1990 or 1992 -1993 . Spirometry was performed in 1989 -1990, and 16 years later. Fibrinogen and CRP were inversely associated with lung function at baseline after adjustment for multiple potential confounders. In mixed models, the rate of decline in forced expiratory volume in 1 second (FEV 1 )/forced vital capacity (FVC) ratio with increasing age was faster among those with higher baseline fibrinogen (À0.032%/year per standard deviation higher fibrinogen (95% confidence interval: À0.057, À0.0074)) but not among those with higher CRP (À0.0037%/year per standard deviation higher CRP (95% confidence interval: À0.013, 0.0056)). Longitudinal analyses for FEV 1 and FVC yielded results in the direction opposite of that hypothesized, possibly because of the high mortality rate and strong inverse association of FEV 1 and FVC but not FEV 1 /FVC with mortality. An alternative approach to missing data yielded similar results. In conclusion, higher levels of fibrinogen, but not CRP, independently predicted greater FEV 1 /FVC decline in the elderly. aged; biological markers; C-reactive protein; fibrinogen; forced expiratory volume; inflammation; spirometry; vital capacity Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; FEV 1 , forced expiratory volume in 1 second; FVC, forced vital capacity.
. COPD morbidity and mortality continue to rise. By the year 2020, COPD is projected to be the third leading cause of death worldwide (5) .
Recent research on the pathogenesis of COPD emphasizes the role of inflammation. It is hypothesized that systemic inflammation may lead to permanent loss of lung function over time by inducing endothelial dysfunction and subsequently causing lung alveolar destruction. Several papers reported that inflammation markers fibrinogen and C-reactive protein (CRP) were inversely associated with lung function in cross-sectional analyses (6) (7) (8) (9) (10) (11) , and other studies have reported that COPD patients had significantly higher levels of fibrinogen and CRP compared with controls (12, 13) .
It is uncertain whether systemic inflammation contributes to accelerated decline in lung function or whether aspects of COPD cause systemic inflammation. Longitudinal studies reporting the association of fibrinogen and CRP levels with lung function decline are sparse. In the Cardiovascular Health Study, a population-based, observational study of cardiovascular disease in the elderly, spirometry was conducted four times over 16 years of follow-up. We examined the association between the inflammatory markers, fibrinogen and CRP, and longitudinal decline in lung function in this large elderly cohort, hypothesizing that higher levels of baseline fibrinogen and CRP predicted greater declines in FEV 1 and the FEV 1 /FVC ratio.
MATERIALS AND METHODS

Study population
The Cardiovascular Health Study is a prospective study of 5,888 men and women aged 65 years or older at baseline designed to investigate risk factors for cardiovascular disease in older adults (14, 15) . A total of 5,201 original cohort subjects (primarily Whites) were initially recruited in 1989-1990 from four US communities: Forsyth County, North Carolina; Sacramento County, California; Washington County, Maryland; and Pittsburgh (Allegheny County), Pennsylvania. An additional 687 African Americans were recruited in 1992-1993 from three of the four counties (Forsyth, Sacramento, and Allegheny) to increase minority representation. The elderly participants were randomly selected from the US Health Care Financing Administration Medicare eligibility lists. Individuals who were institutionalized; were likely to move from the area within the next 3 years; were wheelchair-bound at home; or were receiving hospice treatment, radiation therapy, or chemotherapy for cancer were not eligible to participate. The institutional review board at each participating center approved the study, and all participants gave informed consent.
Extensive data collection was performed at baseline. A subset of the standardized American Thoracic Society DLD-78 Respiratory Questionnaire was administered by a centrally trained interviewer (16) . Other questionnaires were also administered, which collected information on health behaviors and medical conditions. The baseline examination included spirometry, seated blood pressure by random-zero sphygmomanometer, fasting blood chemistry and lipid analysis, and a physical examination. Clinic examinations and telephone contacts occurred annually through 1998-1999, followed by annual phone calls. Spirometry testing was conducted in 1989-1990, 1993-1994, 1996-1997, and 2005-2006 (17) , the latter measure via an ancillary study on lung function in the Cardiovascular Health Study/All Stars examination, an in-person followup examination in 2005-2006 (18) .
In the present study, 39 participants who reported their race as American Indian/Alaskan Native, Asian/Pacific Islander, or other were excluded. Of 5,849 Whites and African Americans, we excluded 98 without fibrinogen and 81 without CRP measures. We further excluded those with unusable baseline spirometry data (missing or spirometry values read from unacceptable curves or unreasonably high or low spirometry values: FEV 1 >5.5, FEV 1 <0.5, FVC >6.0, or FVC <0.5 l) (19) . After the exclusions, 5,011 participants remained for the analysis of fibrinogen and lung function and 5,021 for the analysis of CRP and lung function.
Assessment of inflammatory markers
Blood samples were analyzed at the University of Vermont (Burlington, Vermont) (20) . For the initial cohort, baseline fibrinogen levels in [1989] [1990] were measured with a BBL fibrometer (Becton Dickinson, Cockeysville, Maryland) by the Clauss method with Dade fibrinogen calibration reference (Baxter-Dade, Bedford, Massachusetts) and bovine thrombin (Parke-Davis, Lititz, Pennsylvania) (20) . The mean monthly coefficient of variation was 3.1 percent. Baseline CRP levels were measured by using an enzyme-linked immunosorbent assay (ELISA) developed at the Cardiovascular Health Study central blood laboratory (21) . This colorimetric competitive immunoassay uses purified protein and polyclonal anti-CRP antibodies. The interassay coefficient of variation was 5.5 percent (21) . Fibrinogen and CRP levels were also available in 1992-1993 (3 years of follow-up) for the initial cohort. Fibrinogen levels at 3 years of follow-up were measured by the same method as that used for fibrinogen levels at baseline. The latter measurement of CRP was measured by using the BNII nephelometer from Dade Behring (N High Sensitivity CRP; Dade Behring Inc., Deerfield, Illinois), utilizing particle-enhanced immunonepholometry. The coefficient of variation for this assay was 5.0 percent. Because different assays were used for CRP at baseline and 3 years later, an adjustment was made for the baseline CRP values so that the values obtained from the two assays were directly comparable (CRP_BNII ¼ exp(ln(CRP_ELISA) þ 0.2781)) (22) .
For the African-American cohort, fibrinogen and CRP levels were measured only once at their baseline (1992) (1993) . CRP levels that had been measured by the enzymelinked immunosorbent assay at baseline were remeasured by using the automated BNII assay. In both cohorts, fibrinogen was measured in the same year that blood samples were collected, whereas CRP was measured from stored serum collected at the year. according to American Thoracic Society recommendations (23, 24) . Each spirometer was connected to a personal computer programmed to provide expiratory curves, calculate lung function test parameters, and determine the acceptability of the tests. Checks for leaks and volume accuracy of the spirometer using a 3-l syringe were repeated prior to each session. Internal spirometer temperature was measured for each maneuver and was used for corrections to body temperature, ambient pressure, and saturated water vapor. Participants were asked to perform five to eight forced expiratory maneuvers or until three acceptable and two reproducible maneuvers were obtained. The highest values of FEV 1 and FVC from acceptable maneuvers were used in this analysis.
The quality of the spirometry testing conducted by the technicians was monitored centrally throughout testing. All test sessions were reviewed at the Pulmonary Function Reading Center by a single quality control supervisor (P. L. E.). Five quality control grades were computed separately for FEV 1 and FVC. A grade of A, B, and C met the American Thoracic Society 1994 recommendations (grades from test sessions with two acceptable maneuvers and reproducibility of FEV 1 and FVC values <200 ml) (24). Identical spirometers, software, procedures, and reading center personnel were used at all three examinations, and the majority of the technicians at each of the four clinical sites did not change over time.
The first spirometry for the African-American cohort was performed 1 year later (1993) (1994) , after the recruitment. Therefore, we treated the 1993-1994 spirometry measures as the baseline spirometry measures for the African-American cohort in the analyses.
The Cardiovascular Health Study All-Stars examination was performed in 2005-2006 in participants' homes, nursing homes, or any other convenient location because of the advanced age of the cohort 16 years after its inception. The use of a water-seal spirometer was therefore impractical. Instead, spirometry measures were performed by using the EasyOne Diagnostic portable spirometer (ndd Medical Technologies, Chelmsford, Massachusetts). The reproducibility and validity of this flow-sensing unit has been previously established (25, 26) . The protocol was otherwise the same as for earlier examinations, and all test sessions were reviewed at the Pulmonary Function Reading Center by two quality control supervisors (P. L. E. and R. G. B.). Quality control grades were computed by the EasyOne software and were confirmed by the quality control supervisors.
Test sessions with no acceptable curves at baseline and follow-up examinations were eliminated from the analysis.
Statistical analysis
We analyzed the cross-sectional associations of fibrinogen and CRP levels with lung function at baseline by using generalized linear regression. Longitudinal analyses were conducted by using mixed linear regression models. We modeled the interactions between the inflammatory markers and time as fixed effects, with random subject-specific intercepts. In multivariate models, we controlled for a variety of potential confounders. Smoking status and quality control factors were treated as time varying in longitudinal analyses.
A relatively large proportion of spirometry data was missing in the later years of follow-up because of the high rates of mortality and morbidity in this elderly cohort. Since FEV 1 , FVC, and inflammatory markers predict mortality, these missing data had the potential to bias analyses of longitudinal change in lung function. We used two different approaches to deal with missing spirometry values.
First, we used mixed-effects linear regression models for the main analyses, which are relatively well suited to such problems since they treat missing data as missing at random conditional on the covariates in the model and observed spirometry values. Second, we imputed missing longitudinal spirometry values by using the Markov chain Monte Carlo multiple imputation method based on baseline characteristics including age, gender, height, height squared, FVC, physician diagnosis of emphysema, and updated smoking status (27) . We imputed data sets five times. Each imputed full data set was then analyzed by using a mixed-effects model as described above, providing five sets of parameter estimates. Parameter estimates from each replication of analysis were averaged to provide a single estimate. The standard error of the estimate was computed based on the weighted average of the withinand between-imputation variability of the parameter estimates.
All p values were two tailed, and p values of <0.05 were considered statistically significant. We used SAS software (version 9; SAS Institute, Inc., Cary, North Carolina) for the analyses.
RESULTS
Study population
A total of 5,011 participants had adequate information on fibrinogen and lung function, and 5,021 participants had adequate information on CRP and lung function at baseline. Among the participants, mean age was 72.7 years at baseline; 42.9 percent were male and 87.2 percent were White. Mean baseline FEV 1 , FVC, and FEV 1 /FVC were 2,059 ml, 2,929 ml, and 70.1 percent, respectively. Those participants excluded because of missing measures of fibrinogen and CRP or usable lung function data were more likely to be African American (34.1 percent vs. 12.8 percent in the study population). The distributions of age, gender, height, and smoking status did not differ substantially between the two groups. Those with unusable lung function data had slightly higher median levels of fibrinogen (321 mg/dl vs. 311 mg/dl in the study population) and CRP (2.68 mg/dl vs. 2.51 mg/liter in the study population). Table 1 shows baseline characteristics of study participants by the first, third, and fifth quintiles of baseline levels of fibrinogen and CRP. Compared with participants in the lowest quintile of fibrinogen levels, those in the highest quintile were more likely to be females, African Americans, and current smokers; were heavier; and had a larger waist circumference. Those in the highest fibrinogen quintile were also more likely to have low educational attainment and higher prevalences of self-reported physician-diagnosed asthma, pneumonia, emphysema, and bronchitis. Distributions of participant characteristics by quintiles of CRP levels were similar to those by quintiles of fibrinogen.
Cross-sectional analysis of inflammatory markers and lung function
Baseline fibrinogen and CRP levels were moderately correlated (Spearman correlation coefficient ¼ 0.46; p < 0.0001). Higher levels of fibrinogen were associated with lower FEV 1 and FEV 1 /FVC ratio at baseline (table 2). For each standard deviation higher fibrinogen (66.5 mg/dl), there was a 43.9-ml (95 percent confidence interval (CI): À57.9, À29.9 ml) lower FEV 1 and a 0.33 percent (95 percent CI: À0.60, À0.067 percent) lower FEV 1 /FVC ratio. Associations similar to those for FEV 1 were observed for FVC (table 2) .
Higher levels of CRP were associated with lower FEV 1 and FVC at baseline (table 2). CRP levels were not associated with FEV 1 /FVC ratio (table 2). Every standard deviation higher CRP (2.80 mg/liter) was associated with a 14.3-ml (95 percent CI: À19.1, À9.59 ml) decline in FEV 1 . No linear trend was observed between baseline CRP levels and FEV 1 /FVC ratio in the multivariate model.
Inflammatory markers and longitudinal change in lung function
Retention in the Cardiovascular Health Study, defined as number of participants completing each examination/(baseline number -deaths), was 94.5 percent at the end of the main study period and 85 percent for the Cardiovascular Health Study All-Stars examination. However, the original cohort mortality rates were 9.7 percent after 4 years, 21.1 percent after 7 years, and 62. years later, and 6.31, 3.50, and 13.2 percent of the AfricanAmerican cohort at their baseline and 4 and 13 years later, respectively, were excluded because of nonacceptable curves. In longitudinal analyses using mixed models, higher baseline fibrinogen levels were associated with a faster rate of decline in FEV 1 /FVC with increasing age (À0.032 percent/ year per standard deviation higher fibrinogen (95 percent CI: À0.057, À0.0074; p ¼ 0.01)) during 16 years of follow-up. A trend in the same direction was observed for higher baseline CRP levels, but it was not statistically significant (À0.0037 percent/year per standard deviation higher CRP (95 percent CI: À0.013, 0.0056; p ¼ 0.44)) (table 3) .
Given the large quantity of missing data in the later years of follow-up, we performed additional analyses by using an alternative approach for missing data (table 3) . Qualitatively similar results were obtained with Markov chain Monte Carlo multiple imputation, although the rate of decline in FEV 1 / FVC was marginally nonsignificant for fibrinogen levels.
The rate of decline in the FEV 1 /FVC ratio did not change significantly after we excluded current smokers (À0.033 percent/year per standard deviation higher fibrinogen (95 percent CI: À0.059, À0.007; p ¼ 0.01) and À0.0068 percent/year per standard deviation higher CRP (95 percent CI: À0.016, 0.0028; p ¼ 0.17)). We also examined the rate of decline in FEV 1 /FVC stratified by gender. The differences in the rate of FEV 1 /FVC decline between men and women were not statistically significant (p for interaction was 0.26 for fibrinogen and 0.19 for CRP). In contrast, the rate of decline in FEV 1 with increasing age was not faster among those with higher baseline fibrinogen or CRP levels. The interaction terms for fibrinogen 3 age and CRP 3 age were positive, implying a small, but statistically significant slower decline in FEV 1 among those with higher fibrinogen and higher CRP levels at baseline (table 3) . Findings for FVC were similar to those for FEV 1 .
Updated analyses using time-varying fibrinogen and CRP levels yielded similar results. We further examined the associations of baseline fibrinogen and CRP levels with rate of decline in lung function stratified by baseline lung function, and we found that the association was stronger (greater decline) for FEV 1 /FVC ratio but weaker (slower decline) for FEV 1 and FVC among those with lower baseline lung function (FVC <80 percent predicted or FEV 1 /FVC 0.7) (table 4). Among those with likely COPD at baseline (FEV 1 /FVC <0.65 y Results were adjusted for gender, height, height squared, race/ethnicity, smoking status (never, past, and current), pack-years, educational attainment, weight, waist circumference, use of beta blocker, quality control factors, diagnosed asthma (current vs. other), and diagnosed pneumonia.
z Because the distribution of CRP was highly skewed, the back-transformed SD of lnCRP was used.
and FEV 1 <80 percent of predicted values), the interaction terms for fibrinogen 3 age and CRP 3 age were negative but did not achieve statistical significance.
DISCUSSION
In this large elderly cohort, baseline fibrinogen levels were cross-sectionally, inversely associated with FEV 1 and FEV 1 /FVC ratio, and baseline CRP levels were crosssectionally, inversely associated with FEV 1 and FVC. Elevated levels of fibrinogen predicted greater longitudinal decline in FEV 1 /FVC with increasing age, and a similar, but nonsignificant association was found for CRP. However, contradictory to our hypothesis, higher fibrinogen and CRP levels were associated with small, but statistically significant slower declines in FEV 1 and FVC with increasing age.
Our cross-sectional analyses of fibrinogen and CRP associations with lung function confirmed the findings of previous epidemiologic studies. In the CARDIA Study, FEV 1 and FVC were lower by 166 ml in the highest versus lowest quartile of plasma fibrinogen, although FEV 1 /FVC ratio was unrelated to fibrinogen (6) . Similar inverse associations for fibrinogen and FEV 1 and/or FVC were found in three other studies (none of them examined the associations with FEV 1 / FVC ratio) (7) (8) (9) . Several studies have explored the crosssectional associations between CRP and lung function. A recent study in the United Kingdom analyzed CRP and lung function in 1991 and 2000, respectively, and found that each milligram-per-liter increase in serum CRP was associated with a 9-ml reduction in FEV 1 and an 11-ml reduction in FVC in 1990, and with a 7-ml reduction in FEV 1 and an 8-ml reduction in FVC in 2000 (10) . In the European Community Respiratory Heath Survey, participants in the top tertile of CRP levels had lower FEV 1 and FVC but not a lower FEV 1 /FVC ratio compared with those in the lowest tertile (3.29 liters/second vs. 3.50 liters/second for FEV 1 and 3.97 liters/second vs. 4.16 liters/second for FVC) (11) . In the Third National Health and Nutrition Examination Survey, higher levels of CRP were associated with lower FEV 1 (8) . Increased levels of fibrinogen and CRP have also been reported in individuals with COPD (12, 13) .
Although fibrinogen and CRP have been cross-sectionally associated with lung function and COPD, longitudinal studies on inflammatory markers and change in lung function over time are sparse. We are aware of two published studies that have examined the relation between fibrinogen levels and longitudinal change in lung function. Thyagarajan et al. (6) found that higher fibrinogen levels were associated with greater declines in FEV 1 and FVC but not with FEV 1 / FVC ratio in the much younger CARDIA sample. Donaldson et al. (28) found that higher fibrinogen level was associated with a faster FEV 1 decline in elderly COPD patients. To our knowledge, our study is the first to show an accelerated decline in lung function (FEV 1 /FVC) among those with higher levels of fibrinogen in a population-based elderly cohort. The longitudinal relation between CRP levels and change in lung function has been examined in three published studies, to our knowledge. Fogarty et al. (10) found no association between CRP and decline in FEV 1 and FVC among those aged 18-70 years. Shaaban et al. (29) found that, among those aged 20-44 years, FEV 1 decline tended to increase from the lower to the upper tertile for baseline CRP levels, but the associations were not statistically significant (p ¼ 0.09). Man et al. (30) found that CRP levels were associated with accelerated decline in FEV 1 in cigarette smokers aged 35-60 years with mild to moderate COPD. Of the four longitudinal studies y Results from mixed-effects models were adjusted for gender, height, height squared, race/ethnicity, smoking status (never, past, and current), pack-years, educational attainment, weight, waist circumference, use of beta blocker, quality control factors, diagnosed asthma (current vs. other), and diagnosed pneumonia.
(three previous studies plus ours) on CRP and lung function, three population-based studies did not find a significant relation between CRP and accelerated lung function decline (although a relation for CRP was suggested in two of the studies). The inconsistent results between the three population-based studies and Man et al.'s study of COPD patients could be due to the different study populations. Although contradictory to the hypothesis, it was not surprising to observe that high levels of fibrinogen and CRP were associated with slower decline in FEV 1 and FVC in the Cardiovascular Health Study. First, a previous longitudinal study in the Cardiovascular Health Study found that a diagnosis of emphysema, which was associated with higher fibrinogen and CRP levels, predicted slower decline in FEV 1 and FVC compared with no emphysema (17) . Because emphysema is a subphenotype of COPD, which is characterized by accelerated decline in FEV 1, this finding suggests strong informative censoring by emphysema/COPD deaths in the Cardiovascular Health Study. Second, in the Cardiovascular Health Study, FEV 1 and FVC strongly (relative risk ¼ 6.0) and independently predict death but ratio does not (relative risk ¼ 1.3) (31). Hence, the deaths are likely to strongly bias results for FEV 1 and FVC, but the ratio will be relatively less biased. Third, in our study, the rate of decline in FEV 1 and FVC with increasing fibrinogen or CRP levels was weaker among those with lower baseline lung function (vs. those with normal baseline lung function), suggesting survival bias by FEV 1 and FVC.
In addition to the survival bias, another potential limitation of this study is that the results may not be generalizable to other age groups. Individuals aged 65 years or older may have developed strong resistance to the deterioration in lung function. The strengths of this study include the large cohort with long duration of follow-up, repeated spirometry measures (up to four times), and multiple potential confounders collected.
In conclusion, higher levels of baseline CRP and fibrinogen levels were cross-sectionally associated with lower lung function. Higher levels of fibrinogen, but not CRP, were associated with greater longitudinal declines in FEV 1 /FVC ratio in the elderly.
